Our 2025 Global Biopharma Index highlights that while meaningful progress is being made in supply chain resilience, global disruptions are fueling uncertainty for the future. In fact, a staggering 76% of biopharma leaders surveyed predict that tariffs and trade barriers will significantly affect their sourcing strategies in the upcoming year.
Geopolitical shifts are making it harder for companies to rely on the familiar, linear supply chain management strategies that prioritize cost and efficiency above all else. Organizations are now being forced to adapt quickly, rethink risk, and — importantly — reimagine what true collaboration looks like.
And these effects are already evident on the ground.
Customers are increasingly moving towards regionalization, driven by geopolitical fragmentation and increasing tariff barriers. This can lead to time consuming revalidations and logistical headaches. Research budgets are under pressure amid increasing costs. The regulatory landscape has become more complicated as local priorities take precedence. Overall, these changes are making collaboration between the US, Europe, and China more limited.
It’s clear that the old supply chain playbook can’t keep up with today’s quickly evolving climate. Building supply chain resilience now hinges on adaptability, trust, and a willingness to collaborate across traditional boundaries.
Moving beyond the old vendor model
Supplier relationships in biopharma have historically been transactional and cautious. This is an industry where companies are naturally protective of intellectual property and competitive knowledge.
Whether we’re talking about emissions, supply continuity, or regulatory compliance, the complex challenges of this era can’t be tackled alone. For many companies, the majority of operational and environmental impacts originate upstream, in the supplier network.
What mechanisms do we have in place for addressing these shared risks? Not many.
To build resilience, the industry needs to move beyond transactional relationships and toward true partnerships that acknowledge mutual dependence and align on shared outcomes. There’s still a lot of hesitation around data sharing and transparency, so this shift won’t be easy ― but it is necessary if companies want to manage disruptions efficiently.
Collaboration as a driver of stronger, safer supply chain
As we start to recognize the importance of coming together to address future uncertainties, some companies are already forging new paths. For example, the creation of trade associations that unite competitors reflects a new focus on collective action. These collaborations allow the industry to speak to policymakers with a stronger voice, streamline regulatory processes, and pool resources to tackle mutual challenges. While this model is more common in Europe, there’s a growing sense that similar approaches will be needed globally.
Successful collaboration depends on finding the right balance between openness and protection. Sharing data and know-how can speed up problem-solving and reduce duplication, but it also raises questions about confidentiality and IP.
Building trust takes time and often requires new frameworks ― like NDAs or secure digital platforms ― to enable safe, targeted information exchange. Still, the takeaway is clear: better collaboration leads to faster response to changes in market demand and more robust risk management.
Regionalization: Risk or opportunity?
The shift toward regionalization goes beyond tariff pressures — it’s a deliberate risk mitigation strategy. Companies that leaned into in-region, for-region manufacturing during the pandemic are now better positioned to weather disruptions.
Rather than seeing regionalization as a threat, forward-thinking organizations are viewing it as an opportunity to diversify, strengthen local expertise, and create more resilient global networks.
Building resilience across regions still requires collaboration. Regulatory differences, resource constraints, and the need for local adaptation mean that companies must work closely with both local partners and global suppliers. These efforts often include developing shared regulatory roadmaps, investing in training, and supporting customers as they navigate complex market requirements.
Rethinking supply chain management, together
Navigating this new environment means re-evaluating not just the risks of taking action, but also the risks of standing still. All players, suppliers, manufacturers, and customers need to be on board with a new era of supply chain management, even if it means moving past some long-held reservations.
Ultimately, the path to true supply chain resilience lies in building partnerships founded on trust, transparency, and a shared sense of purpose. No company can do it alone, and no single region has all the answers. By working together, within regions, across borders, and up and down the supply chain, the biopharma industry can build the collaborative muscle it needs to thrive, whatever tomorrow brings.